121 related articles for article (PubMed ID: 9402326)
1. Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials.
Myers DE; Jun X; Clementson D; Donelson R; Sicheneder A; Hoffman N; Bell K; Sarquis M; Langlie MC; Turner N; Uckun FM
Leuk Lymphoma; 1997 Oct; 27(3-4):275-302. PubMed ID: 9402326
[TBL] [Abstract][Full Text] [Related]
2. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
Waurzyniak B; Schneider EA; Tumer N; Yanishevski Y; Gunther R; Chelstrom LM; Wendorf H; Myers DE; Irvin JD; Messinger Y; Ek O; Zeren T; Langlie MC; Evans WE; Uckun FM
Clin Cancer Res; 1997 Jun; 3(6):881-90. PubMed ID: 9815763
[TBL] [Abstract][Full Text] [Related]
3. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
4. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials.
Myers DE; Irvin JD; Smith RS; Kuebelbeck VM; Uckun FM
J Immunol Methods; 1991 Feb; 136(2):221-37. PubMed ID: 1705571
[TBL] [Abstract][Full Text] [Related]
5. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
6. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
7. TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus.
Uckun FM; Chelstrom LM; Tuel-Ahlgren L; Dibirdik I; Irvin JD; Langlie MC; Myers DE
Antimicrob Agents Chemother; 1998 Feb; 42(2):383-8. PubMed ID: 9527790
[TBL] [Abstract][Full Text] [Related]
8. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus.
Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL
J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
[TBL] [Abstract][Full Text] [Related]
10. Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation.
Ramakrishnan S; Uckun FM; Houston LL
J Immunol; 1985 Nov; 135(5):3616-22. PubMed ID: 3900212
[TBL] [Abstract][Full Text] [Related]
11. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
Uckun FM; Manivel C; Arthur D; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Gunther R
Blood; 1992 May; 79(9):2201-14. PubMed ID: 1373967
[TBL] [Abstract][Full Text] [Related]
12. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
Uckun FM; Myers DE; Irvin JD; Kuebelbeck VM; Finnegan D; Chelstrom LM; Houston LL
Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916
[TBL] [Abstract][Full Text] [Related]
13. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
Flavell DJ; Warnes S; Noss A; Flavell SU
Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737
[TBL] [Abstract][Full Text] [Related]
14. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
[TBL] [Abstract][Full Text] [Related]
15. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.
Vallera DA; Burns LJ; Frankel AE; Sicheneder AR; Gunther R; Gajl-Peczalska K; Pennell CA; Kersey JH
J Immunol Methods; 1996 Oct; 197(1-2):69-83. PubMed ID: 8890895
[TBL] [Abstract][Full Text] [Related]
16. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.
Myers DE; Uckun FM
Leuk Lymphoma; 1995 Jun; 18(1-2):119-22. PubMed ID: 8580813
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
[TBL] [Abstract][Full Text] [Related]
18. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.
Myers DE; Yanishevski Y; Masson E; Irvin JD; Evans WE; Uckun FM
Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal anti-human T cell antibody and PAP-s conjugate--preparation and selective cytotoxic properties on leukemic cell.
Chu JY; Yang AD; Wang BM; Hu Z; Zhu XM; Zhang HJ; Qu JH; Luo LY; Guo R; Shi LR
J Tongji Med Univ; 1990; 10(1):15-8. PubMed ID: 2348483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
